Overview

Sitosterolemia Metabolism

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
0
Participant gender:
All
Summary
Ezetimibe has become the treatment choice for patients with sitosterolemia. Ezetimibe is an inhibitor of cholesterol absorption from the gastrointestinal tract. The purpose of this study is to determine if ezetimibe improves whole body plant sterol and cholesterol homeostasis.
Phase:
N/A
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
University of Manitoba
Treatments:
Ezetimibe
Criteria
Inclusion Criteria:

- confirmed diagnosis of homozygous sitosterolemia as established by genotyping and
clinical parameters

Exclusion Criteria:

- pregnant

- intellectual disability

- major infectious diseases

- immunodeficiency

- cancer

- renal failure

- diabetes